Condition: Carcinoma, Intraductal, Noninfiltrating · Sponsor: Universität Münster
DCIS (ductal carcinoma in situ) is a common pre-stage for breast cancer. The goal of this clinical trial is to learn if FAPI-PET/MRI (an imaging technique with a weakly radioactive drug) helps to diagnose hidden invasive breast cancer in participants with DCIS. The main question it aims to answer is: How good can FAPI-PET/MRI diagnose hidden invasive breast cancer in DCIS? Researchers will compare FAPI-PET/MRI results to tissue samples obtained from surgery treatment to see if the FAPI-PET/MRI images show invasive breast cancer certainly. Participants will * receive the radioactive drug and lie in an imaging device for 45 minutes including a break * visit the clinic once again for a checkup and test
This description comes directly from the study's public registry record.
Philipp Backhaus, Dr. med. · +4925183 · nuklearmedizin@ukmuenster.de
Matthias Burg, Dr. med. · +4925183 · radiologie@ukmuenster.de
Always discuss trial participation with your own doctor first.
| Department of Nuclear Medicine, University Hospital Essen | Essen, North Rhine-Westphalia, Germany | Not Yet Recruiting |
| Department of Nuclear Medicine, University Hospital Münster | Münster, North Rhine-Westphalia, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06540872